VisionCare, Inc. has announced FDA approval to study the company’s Implantable Miniature Telescope (IMT) in patients who have been previously treated for cataract. In the study, the new intraocular lens will be removed and replaced with the IMT in order to evaluate the safety and effectiveness of the device.
For the past 8 years, the telescope implant has been improving visual acuity and quality of life for patients with end-stage macular degeneration. It is the only FDA-approved surgical device for this condition, and it is Medicare eligible.
The telescope implant is not currently available to patients with previous intraocular or corneal surgery of any kind in the operative eye, including any type of surgery for either refractive or therapeutic purposes. Now, however, selected CentraSight providers across the country will be seeking end-stage macular degeneration patients with previous cataract surgery to determine if they might be candidates as study subjects for the telescope implant.
Patients and physicians can learn more about the telescope implant by visiting https://lowvisioninstitute.com/low-vision-aids-devices-and-glasses/centrasight/#:~:text=What%20is%20CentraSight?%20The%20CentraSight%20treatment%20program%20uses or calling 1-877-99-SIGHT.
Source:
